South Africa: The First Generic Weight Loss Drug Hit South Africa In August - With Many Expected To Follow. Will It Be Enough To Kill The Black Market?

What the report says

South Africa’s first generic semaglutide injection became available in August, according to Bhekisisa Centre for Health Journalism, in a development that could begin easing the high cost of GLP-1 medicines used for diabetes and weight loss. The article says South Africa’s regulator is also reviewing 13 more applications, suggesting broader generic competition may follow. Semaglutide is the ingredient in branded products such as Ozempic and Wegovy.

The report says the new generic is only around 18.5% cheaper than Ozempic, which may not be enough on its own to make treatment widely affordable. It notes that researchers have estimated semaglutide could eventually be produced for far less, potentially changing the market if prices fall substantially. Bhekisisa also points out that high demand and limited supply have already helped create a black market for unregistered weight-loss injections.

A key issue, the article says, is access in South Africa’s health system: about 84% of residents depend on public healthcare, so lower prices in private pharmacies may not help most patients unless the state buys these medicines. The piece adds that some people have turned to compounded or unregistered products because of shortages and cost, raising safety concerns about what is actually being injected.

The article’s broader context is that GLP-1 drugs have become a fast-growing global market, but the combination of strong demand, patent expiries in some countries and uneven access is putting pressure on regulators, manufacturers and health systems. The central question remains whether generics will be cheap enough, and available enough, to undercut illegal suppliers and expand legitimate treatment.